None listed
Conditions
Interventions
A beverage not containing heat-killed Labre per day for 12 weeks.
A beverage containing heat-killed Labre (low-dose) per day for 12 weeks.
A beverage containing heat-killed Labre (high-dose) per day f
Sponsors
Kagome Co., Ltd.
KSO Corporation
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)Japanese male and female aged 20 to 64 years-old at acquisition of the consent. (2)Whose BMI are 23 or more and less than 30 at screening test. (3)Who can make self-judgment, voluntarily agreed to participate to this study, and provide written informed consent.
Exclusion criteria
Exclusion criteria: (1)Who use medicines that may affect obesity, hyperlipidemia, lipid metabolism. (2)Who has such serious diseases as liver disease, cardiovascular disease, respiratory disease, endocrine disorder, metabolic disease, food allergy disease. (3)Who cannot stop intake health foods or supplements which may affect obesity, hyperlipidemia, lipid metabolism, during this study. (4)Who has a current or history of drug dependence and/or alcoholism. (5)Who has been implanted metal in the DUAL SCAN measurement site. (6)Who has implantable medical devices (e.g., cardiac pacemaker and/or implantable defibrillator). (7)Who has been diagnosed as familial hyperlipidemia. (8)Who is pregnant or breast-feeding or willing to be pregnant during this study. (9)Who has an irregular diet, and/or is shift worker and/or midnight-shift worker. (10)Who is planning to participate and/or has participated in other clinical studies. (11)Who is judged as unsuitable for this study by the principal investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visceral fat area | — |
Secondary
| Measure | Time frame |
|---|---|
| Abdominal subcutaneous fat area, total fat area, body weight (BMI), blood pressure, body fat percentage, muscle mass, waist/hip circumference, AST (GOT), ALT (GPT), gamma-GTP, total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, blood glucose level, insulin, HbA1c, HOMA-IR, fecal microbiota. | — |
Countries
Japan
Contacts
Public ContactYoshika Komori
KSO Corporation Sales department
Outcome results
None listed